Skip to main content

Table 2 Proportion of patients treated with bevacizumab among patients who received chemotherapy, and predictors of treatment with bevacizumab in first line, adjusted for all factors listed (n = 361)

From: Bevacizumab for metachronous metastatic colorectal cancer: a reflection of community based practice

N = 361 N (%) OR 95 % CI
Gender     
 Male 72 (49) Ref  
 Female 113 (53) 1.3 0.79–2.16
Age (years)     
  < 60 57 (60) Ref  
 60–74 111 (56) 1.1 0.61–2.05
  ≥ 75 17 (26) 0.5 0.22–1.27
Comorbidity     
 No 81 (62) Ref  
 1 comorbid condition 56 (54) 0.8 0.42–1.45
  ≥ 2 comorbid conditions 33 (34) 0.4 0.21–0.81
 Unknown 15 (48) 0.7 0.27–1.65
Primary tumor localization     
 Rectum 85 (55) Ref  
 Colon 100 (48) 0.9 0.37–2.26
Adjuvant chemotherapy     
 No 100 (49) Ref  
 Yes 85 (54) 1.7 0.98–2.96
Time to metastases (years)     
  < 1 year 43 (43) Ref  
 1–2 years 71 (55) 1.5 0.78–2.82
  ≥ 2 years 71 (53) 1.2 0.60–2.30
Period of diagnosis metastasis     
 2005–2006 41 (37) Ref  
 2007–2008 78 (58) 3.0 1.62–5.70
 2009–2011 66 (57) 3.3 1.67–6.74
Number of organs affected     
 1 organ 85 (54) Ref  
 2 organs 59 (46) 0.5 0.29–0.91
  ≥ 3 organs 41 (53) 0.9 0.46–1.74
First-line chemotherapy     
 Single agent chemotherapy 32 (23) Ref  
 Combination chemotherapy 153 (70) 9.6 5.43–17.05
  1. N; number of patients receiving bevacizumab in the first-line of systemic treatment
  2. %; percentage of patients receiving bevacizumab in the first-line of systemic treatment
  3. OR odds ratio, CI confidence interval
  4. Bold data; P-value <0.05